专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09233112B2 Pharmaceutical compositions of cefixime 有权
标题翻译：头孢克肟的药物组合物
公开(公告)号：US09233112B2
公开(公告)日：2016-01-12
申请号：US13156146
申请日：2011-06-08
申请人： Shrenik Annasaheb Kole , Bharat Raghunath Metkar , Makarand Krishnakumar Avachat
发明人： Shrenik Annasaheb Kole , Bharat Raghunath Metkar , Makarand Krishnakumar Avachat
IPC分类号： A61K31/546 , A61P31/04 , A61K9/00 , A61K9/10
CPC分类号： A61K31/546 , A61K9/0095 , A61K9/10
摘要： A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients.
摘要翻译：包含大于80mg / ml且不超过150mg / ml的头孢克肟和药学上可接受的赋形剂的药物悬浮剂剂型。

2. 发明申请

US20110123609A1 MULTIPLE UNIT DOSAGE FORM OF NIACIN 审中-公开
标题翻译： NIACIN多单位剂型
公开(公告)号：US20110123609A1
公开(公告)日：2011-05-26
申请号：US13054901
申请日：2009-07-16
申请人： Sunil Shantwan Borude , Shrenik Annasaheb Kole , Makarand Krishnakumar Avachat
发明人： Sunil Shantwan Borude , Shrenik Annasaheb Kole , Makarand Krishnakumar Avachat
IPC分类号： A61K9/48 , A61K31/455 , A61P3/06
CPC分类号： A61K9/4808 , A61K9/5047 , A61K9/5084 , A61K31/366 , A61K31/40 , A61K31/455 , A61K45/06 , A61K2300/00
摘要： A multiple unit dosage form useful for treating or preventing hyperlipidemia and/or atherosclerosis, wherein multiple unit dosage form comprise of a therapeutically effective amount of niacin or its derivatives and one or more control releasing agent(s) and pharmaceutically acceptable excipients, weight percentages are based upon the total weight of the dosage form. The multiple unit dosage form may comprise of optionally other antihyperlipidemic agent, more preferably HMG CoA reductase inhibitor. The most preferable dosage form is capsule. Further a kit comprising one or more capsules co-packaged to provide multiple unit dosage form of niacin or its derivatives in combination with HMG CoA reductase inhibitor is disclosed.
摘要翻译：可用于治疗或预防高脂血症和/或动脉粥样硬化的多单位剂型，其中多个单位剂型包含治疗有效量的烟酸或其衍生物和一种或多种对照释放剂和药学上可接受的赋形剂，重量百分数为基于剂型的总重量。多单位剂型可任选地包含其它抗高血脂药，更优选HMG CoA还原酶抑制剂。最优选的剂型是胶囊。此外，公开了一种试剂盒，其包含一个或多个胶囊，其共同包装以提供多种单位剂型的烟酸或其衍生物与HMG CoA还原酶抑制剂的组合。

3. 发明申请

US20110020439A1 DELAYED RELEASE COMPOSITIONS OF DULOXETINE 审中-公开
标题翻译：延迟释放DULOXETINE的组合物
公开(公告)号：US20110020439A1
公开(公告)日：2011-01-27
申请号：US12934148
申请日：2009-03-17
申请人： Shrenik Annasaheb Kole , Ashok Kumar Sahoo , Makarand Krishnakumar Avachat
发明人： Shrenik Annasaheb Kole , Ashok Kumar Sahoo , Makarand Krishnakumar Avachat
IPC分类号： A61K31/381 , A61K9/52 , A61K9/22 , A61P25/00 , A61P25/22 , A61P25/24 , B05D5/00
CPC分类号： A61K31/381 , A61K9/2072 , A61K9/2866 , A61K9/2886 , A61K9/4808
摘要： A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s) thereof; intermediate layer; and enteric layer; wherein the dosage form comprises one/more dissolution enhancer(s), wherein the enteric layer comprises one/more enteric polymers other than hydroxypropylmethyl acetate succinate. A process of preparing a delayed release dosage comprising mixing pharmaceutically acceptable excipients with duloxetine or its pharmaceutically acceptable derivatives thereof; granulating the product of previous step compressing the granulate formed in previous step to form core, coating said core with intermediate layer followed by coating with one/more enteric polymers and optional finishing coating. A delayed release dosage form comprising: core comprising duloxetine or its pharmaceutically acceptable derivative thereof, intermediate layer and enteric layer comprising one/more enteric polymers other than hydroxypropylmethyl acetate succinate; wherein dosage form contains one/more dissolution enhancer(s) and has improved dissolution.
摘要翻译：延迟释放剂型，其包含核心，其包含度洛西汀或其药学上可接受的盐或衍生物，任选地，其它药学上可接受的赋形剂; 中间层肠溶层; 其中所述剂型包含一种或多种溶出增强剂，其中所述肠溶层包含除了羟丙基甲基醋酸琥珀酸酯之外的一种/多种肠溶聚合物。制备延迟释放剂量的方法，包括将药学上可接受的赋形剂与度洛西汀或其药学上可接受的衍生物混合; 造粒前一步骤的产品压缩前一步骤形成的颗粒以形成芯，用中间层涂覆所述芯，然后用一种/多种肠溶聚合物和可选的整理涂层进行包衣。延迟释放剂型，其包含：包含度洛西汀或其药学上可接受的衍生物的核心，中间层和肠溶层，其包含除羟丙基甲基醋酸琥珀酯之外的一种/多种肠溶聚合物; 其中剂型含有一种/多种溶解增强剂并具有改善的溶解。

4. 发明申请

US20130122090A1 Multiple Unit Tablet Composition 审中-公开
标题翻译：多单位片剂成分
公开(公告)号：US20130122090A1
公开(公告)日：2013-05-16
申请号：US13811327
申请日：2011-07-18
申请人： Sunil Shantwan Borude , Shrenik Annasaheb Kole , Makrand Krishnakumar Avachat
发明人： Sunil Shantwan Borude , Shrenik Annasaheb Kole , Makrand Krishnakumar Avachat
IPC分类号： A61K9/28 , A61K31/4439 , A61K9/20
CPC分类号： A61K9/28 , A61K9/2081 , A61K9/2095 , A61K9/501 , A61K9/5047 , A61K9/5078 , A61K31/4439
摘要： A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer; at least two diluents and optionally one or more other pharmaceutically acceptable excipient, wherein one diluent is highly compactable microcrystalline cellulose and process for preparing the same.
摘要翻译：一种多单位片剂组合物，其包含包含药物活性成分的肠溶衣多单位核心，其中肠溶衣的增塑剂含量小于肠溶衣聚合物的约10重量％至少两种稀释剂和任选的一种或多种其它药学上可接受的赋形剂，其中一种稀释剂是高度可压缩的微晶纤维素及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式